The global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market has been boosted by recent FDA approval for Prolastin-C. According to a report published by Fortune Business Insights, titled “AATD Augmentation Therapy: Global Analysis, Insights and Forecast, 2019-2026”, the market will be valued at US$ 1959.8 Mn by the end of 2025. The estimated rise in market value from its 2017 value of US$ 1115.5 Mn implies that the market will exhibit a CAGR of 5.9% in the forecast period. Fortune Business Insights expects that factors such as regulatory approvals and improvements in augmentation therapies will drive the market in this period.
Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/sample/aatd-augmentation-therapy-market-100169
What is the Scope of this market?
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
Geographical Analysis:
- North America (The U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)
- Latin America (Brazil, Mexico, and the Rest of Latin America)
- The Middle East & Africa (South Africa, GCC, and the Rest of the Middle East & Africa)
Grifols SA’s AlfaCare Program Has Had a Positive Impact on the Global Market
In November 2018, Grifols Sa introduced AlfaCare, a therapy program aimed at providing training and counselling to patients diagnosed with AATD. Grifols stated that with AlfaCare, it aims to encourage new habits in AATD patients and help them manage their disease properly. Research studies have proven that a huge percentage of people diagnosed with AATD were unaware about the symptoms, effects, and ways to treat the disorder. AlfaCare was launched to overcome all such shortcomings and improve the quality of patient care, thereby ascertaining reduced fatality rate of AATD. Thus, AlfaCare has transformed AATD augmentation therapies worldwide and is likely to boost the global AATD augmentation therapy market in the forecast period.
To get to know more about the short-term and long-term impact of COVID-19 on this market,
Please Visit: https://www.fortunebusinessinsights.com/industry-reports/aatd-augmentation-therapy-market-100169
North America to Dominate the Global Market
Rising number of AATD cases in North America is fuelling the demand for AATD augmentation therapy in this region. This in turn has led to the growth of AATD augmentation therapy market in North America and is likely to favor growth of the market in this region through the forecast period. There have been significant improvements in AATD diagnostic techniques used in many parts of Asia Pacific. Furthermore, the emphasis on AATD by the government in Asia Pacific is likely to enable growth in the regional market in the forthcoming years. Despite North America’s dominance, Asia Pacific will emerge as the fastest growing region in the forecast period.
Related Reports :